Veda N. Giri

3.6k total citations
79 papers, 1.2k citations indexed

About

Veda N. Giri is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Veda N. Giri has authored 79 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Genetics, 33 papers in Pulmonary and Respiratory Medicine and 23 papers in Oncology. Recurrent topics in Veda N. Giri's work include BRCA gene mutations in cancer (37 papers), Prostate Cancer Treatment and Research (28 papers) and Prostate Cancer Diagnosis and Treatment (16 papers). Veda N. Giri is often cited by papers focused on BRCA gene mutations in cancer (37 papers), Prostate Cancer Treatment and Research (28 papers) and Prostate Cancer Diagnosis and Treatment (16 papers). Veda N. Giri collaborates with scholars based in United States, United Kingdom and Australia. Veda N. Giri's co-authors include Jennifer Beebe‐Dimmer, Michael J. Hall, Colette Hyatt, Leonard G. Gomella, Stacy Loeb, Karen Ruth, Andrea Forman, Deborah Watkins Bruner, Sarah Hegarty and Georgia L. Wiesner and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

Veda N. Giri

75 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Veda N. Giri United States 20 510 422 368 256 246 79 1.2k
Chiledum Ahaghotu United States 21 406 0.8× 314 0.7× 265 0.7× 330 1.3× 151 0.6× 39 1.2k
Shulamith Rizel Israel 18 206 0.4× 329 0.8× 526 1.4× 273 1.1× 418 1.7× 46 1.2k
Jerzy E. Tyczynski United States 15 291 0.6× 231 0.5× 438 1.2× 213 0.8× 124 0.5× 38 1.1k
Uwe Güth Switzerland 22 178 0.3× 165 0.4× 694 1.9× 205 0.8× 457 1.9× 102 1.4k
Carmel Apicella Australia 22 230 0.5× 562 1.3× 584 1.6× 259 1.0× 306 1.2× 39 1.2k
Kathleen Herkommer Germany 21 548 1.1× 135 0.3× 241 0.7× 185 0.7× 147 0.6× 96 1.2k
Martina Dünser Austria 15 227 0.4× 99 0.2× 514 1.4× 175 0.7× 334 1.4× 22 1.2k
Susan Randall Armel Canada 21 111 0.2× 963 2.3× 536 1.5× 331 1.3× 352 1.4× 51 1.5k
Christopher Wale United Kingdom 9 300 0.6× 553 1.3× 987 2.7× 269 1.1× 1.2k 4.7× 9 1.8k
Helen Krontiras United States 24 181 0.4× 197 0.5× 829 2.3× 489 1.9× 563 2.3× 71 1.7k

Countries citing papers authored by Veda N. Giri

Since Specialization
Citations

This map shows the geographic impact of Veda N. Giri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veda N. Giri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veda N. Giri more than expected).

Fields of papers citing papers by Veda N. Giri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veda N. Giri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veda N. Giri. The network helps show where Veda N. Giri may publish in the future.

Co-authorship network of co-authors of Veda N. Giri

This figure shows the co-authorship network connecting the top 25 collaborators of Veda N. Giri. A scholar is included among the top collaborators of Veda N. Giri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veda N. Giri. Veda N. Giri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Evan Y., R. Bryan Rumble, Neeraj Agarwal, et al.. (2025). Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology. 43(6). 748–758. 10 indexed citations
2.
Leader, Amy, et al.. (2025). A Social Media Campaign and Web-Based Survey About Prostate Cancer Genetics: Mixed Methods Study. JMIR Cancer. 11. e69787–e69787.
3.
Giri, Veda N., et al.. (2025). Knowledge and attitudes toward prostate cancer germline genetic testing among Hispanic males. Prostate Cancer and Prostatic Diseases.
4.
Pal, Subhamoy, Wendy R. Uhlmann, Kunal Sanghavi, et al.. (2024). Health care utilization and behavior changes after workplace genetic testing at a large US health care system. Genetics in Medicine. 26(8). 101160–101160. 4 indexed citations
5.
Seibert, Tyler M., Isla P. Garraway, Anna Plym, et al.. (2023). Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology. 83(3). 241–248. 24 indexed citations
6.
Gomella, Patrick T., James Ryan Mark, Veda N. Giri, William Kevin Kelly, & Leonard G. Gomella. (2022). Guidelines on Germline Testing for Urologic Tumor Syndromes. European Urology Focus. 8(3). 670–673. 3 indexed citations
7.
Mark, James Ryan, Carey McDougall, & Veda N. Giri. (2021). Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. Urologic Clinics of North America. 48(3). 311–322. 3 indexed citations
8.
Loeb, Stacy, Randall Li, Nataliya Byrne, et al.. (2021). Barriers and facilitators of germline genetic evaluation for prostate cancer. The Prostate. 81(11). 754–764. 24 indexed citations
9.
Loeb, Stacy, Philip M. Massey, Amy Leader, et al.. (2021). Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis. JMIR Cancer. 7(3). e27063–e27063. 13 indexed citations
10.
Loeb, Stacy, Nataliya Byrne, Dawn Walter, et al.. (2020). Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation✰,✰✰. Cancer Treatment and Research Communications. 25. 100212–100212. 22 indexed citations
11.
12.
Roussi, Pagona, Suzanne M. Miller, Veda N. Giri, et al.. (2016). Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style. Journal of Health Psychology. 23(14). 1800–1809. 7 indexed citations
13.
Myers, Ronald E., Amy Leader, Edouard J. Trabulsi, et al.. (2016). Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. Journal of Cancer Education. 33(1). 180–185. 12 indexed citations
14.
Chang, Bao‐Li, et al.. (2013). Validation of association of genetic variants at 10q with prostate‐specific antigen ( PSA ) levels in men at high risk for prostate cancer. British Journal of Urology. 113(5b). E150–6. 5 indexed citations
15.
Ross, Eric A., Robert G. Uzzo, David Y.T. Chen, et al.. (2012). Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection. Cancer Epidemiology Biomarkers & Prevention. 21(1). 53–60. 11 indexed citations
16.
Giri, Veda N., Karen Ruth, Robert G. Uzzo, et al.. (2010). Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val. British Journal of Urology. 107(3). 466–470. 15 indexed citations
17.
Giri, Veda N., et al.. (2009). Met160Val TMPRSS2 gene polymorphism and early onset prostate cancer in high-risk men. Journal of Clinical Oncology. 27(15_suppl). 5000–5000. 1 indexed citations
18.
Hayward, Rodney A., Claude L. Cowan, Veda N. Giri, Mary Lawrence, & Fatima Makki. (2005). Causes of preventable visual loss in type 2 diabetes mellitus. Journal of General Internal Medicine. 20(5). 467–469. 6 indexed citations
19.
Giri, Veda N., et al.. (2004). Association between Agent Orange and prostate cancer: a pilot case-control study. Urology. 63(4). 757–760. 27 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chiledum Ahaghotu Breakdown of academic impact, for papers by Shulamith Rizel Breakdown of academic impact, for papers by Jerzy E. Tyczynski Breakdown of academic impact, for papers by Uwe Güth Breakdown of academic impact, for papers by Carmel Apicella Breakdown of academic impact, for papers by Kathleen Herkommer Breakdown of academic impact, for papers by Martina Dünser Breakdown of academic impact, for papers by Susan Randall Armel Breakdown of academic impact, for papers by Christopher Wale Breakdown of academic impact, for papers by Helen Krontiras
Rankless by CCL
2026